Articles

Palantir’s biggest stock-market bull ups the ante after 54% rally this year

Palantir is proving itself “a clear leader in the AI arms race,” says Wedbush.

This is how the government’s financial-aid form delay is hurting college students like us

Students who need to know how much financial aid they’re getting in order to make their college decision are bearing the brunt of this year’s “dysfunctional” FAFSA rollout.

Buy the pound, Bank of America says, as U.K. currency hits seven-month high

A somewhat softer-than-expected U.S. jobs report released Friday contributed to the British pound gaining 0.5% to trade at $1.287, the highest level since July.

Amylyx Pharmaceuticals stock drops 80% after ALS drug fails late-stage trial

Amylyx Pharmaceuticals shares dropped more than 80% early Friday after the company said its ALS treatment Relyvrio failed a late-stage trial and may be pulled from the market.

Apple’s stock pressure could continue for months, this bull concedes

Smartphone demand has been sluggish, though the June WWDC event could show how Apple plans to capitalize on AI.

Costco isn’t raising its membership fee. Analysts are disappointed.

Costco, which reported fourth-quarter results Thursday, last raised its annual membership in 2017.

GE draws upgrade to outperform at JPMorgan ahead of its split into two companies

The industrial giant was praised as a “premium large-cap name” in commercial aerospace.

Broadcom earnings spotlight tech’s growing AI ‘dichotomy’

There’s artificial intelligence, and then there’s everything else. That’s essentially Wall Street’s takeaway from Broadcom’s earnings.

Prada adds nearly $3 billion in market cap after 44% earnings surge

Prada gained about $2.70 billion in market value after annual profit and sales surged past analysts’ expectations, outperforming other European luxury-goods firms that are grappling with a slowdown in the industry.

Oil prices trade lower ahead of U.S. jobs report

Oil futures are on track for a losing week.

NYCB’s new chief executive and capital infusion draw praise but risks remain

Moody’s reviews NYCB for upgrade, while DA Davidson flags deposit flight and threat to credit quality due to multifamily loan exposures

Eli Lilly’s stock dips as Alzheimer’s drug delayed by surprise FDA panel meeting

The FDA is seeking to further understand topics related to evaluating the safety and efficacy of the drug, including results in patients who have taken it and the efficacy implications of the trial design.
1 710 711 712 713 714 1,645